107 222

Cited 9 times in

Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response

DC FieldValueLanguage
dc.contributor.author정문재-
dc.contributor.author정재복-
dc.contributor.author박승우-
dc.contributor.author박정엽-
dc.contributor.author방승민-
dc.contributor.author송시영-
dc.date.accessioned2014-12-18T09:20:02Z-
dc.date.available2014-12-18T09:20:02Z-
dc.date.issued2013-
dc.identifier.issn1976-2283-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/87976-
dc.description.abstractBACKGROUND/AIMS: Erlotinib and gemcitabine combined chemotherapy is becoming the treatment of choice in advanced pancreatic cancer. We evaluated the effectiveness of treatment with erlotinib plus gemcitabine and the prognostic factors for chemotherapeutic response in Korean pancreatic cancer patients. METHODS: Sixty-nine patients with advanced pancreatic cancer who were treated with daily erlotinib 100 mg orally and gemcitabine 1,000 mg/m(2)/30 min intravenous infusion on days 1, 8, and 15 of each 4-week cycle from 2006 to 2009 were included in this study. This study was a phase II single-center trial. RESULTS: All 69 patients with advanced pancreatic cancer were chemotherapy-naïve. The objective response rate was 18.8%, and the overall tumor-stabilization rate was 49.2%. The median overall survival was 7.7 months (95% confidence interval [CI], 6.0 to 9.4 months). The median progression-free survival was 1.9 months (95% CI, 1.4 to 2.5 months). Prognostic factors for good chemotherapeutic response were good performance status and the presence of skin rash during chemotherapy. Patients with lower performance scores showed worse chemotherapeutic responses (odds ratio [OR], 7.6; 95% CI, 2.4 to 24.8). Poor responses were predicted by the absence of skin rash during chemotherapy (OR, 3.0; 95% CI, 1.4 to 6.3). CONCLUSIONS: Erlotinib and gemcitabine chemotherapy is a tolerable treatment regimen and has a favorable therapeutic effect in Korean patients with advanced pancreatic cancer.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfGUT AND LIVER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titlePhase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorSemi Park-
dc.contributor.googleauthorMoon Jae Chung-
dc.contributor.googleauthorJeong Youp Park-
dc.contributor.googleauthorJae Bock Chung-
dc.contributor.googleauthorSeungmin Bang-
dc.contributor.googleauthorSeung Woo Park-
dc.contributor.googleauthorSi Young Song-
dc.identifier.doi10.5009/gnl.2013.7.5.611-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03602-
dc.contributor.localIdA03706-
dc.contributor.localIdA01551-
dc.contributor.localIdA01647-
dc.contributor.localIdA01786-
dc.contributor.localIdA02035-
dc.relation.journalcodeJ00954-
dc.identifier.eissn2005-1212-
dc.identifier.pmid24073321-
dc.subject.keywordErlotinib-
dc.subject.keywordGemcitabine-
dc.subject.keywordPancreatic neoplasms-
dc.contributor.alternativeNameChung, Moon Jae-
dc.contributor.alternativeNameChung, Jae Bock-
dc.contributor.alternativeNamePark, Seung Woo-
dc.contributor.alternativeNamePark, Jeong Youp-
dc.contributor.alternativeNameBang, Seung Min-
dc.contributor.alternativeNameSong, Si Young-
dc.contributor.affiliatedAuthorChung, Moon Jae-
dc.contributor.affiliatedAuthorChung, Jae Bock-
dc.contributor.affiliatedAuthorPark, Seung Woo-
dc.contributor.affiliatedAuthorPark, Jeong Youp-
dc.contributor.affiliatedAuthorBang, Seung Min-
dc.contributor.affiliatedAuthorSong, Si Young-
dc.rights.accessRightsfree-
dc.citation.volume7-
dc.citation.number5-
dc.citation.startPage611-
dc.citation.endPage615-
dc.identifier.bibliographicCitationGUT AND LIVER, Vol.7(5) : 611-615, 2013-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.